- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Grace Announces Silica-based Drug Delivery Platform
PTSM: Pharmaceutical Technology Sourcing and Management
Grace and Formac Pharmaceuticals have announced SilSol 6035 Mesoporous Silica Gel, the first silica in the Grace silica-based drug delivery platform. The silica gel is the result of a multi-year collaboration between the companies.The platform was engineered to offer a new drug delivery option for APIs with poor aqueous solubility (BCS class 2 compounds), Grace reports and combines the company’s expertise in mesoporous silica gel and novel application methods to accelerate the screening and development of stable, amorphous-based systems.
Grace and Formac Pharmaceuticals have announced SilSol 6035 Mesoporous Silica Gel, the first silica in the Grace silica-based drug delivery platform. The silica gel is the result of a multi-year collaboration between the companies.
The platform was engineered to offer a new drug delivery option for APIs with poor aqueous solubility (BCS class 2 compounds), Grace reports and combines the company’s expertise in mesoporous silica gel and novel application methods to accelerate the screening and development of stable, amorphous-based systems.
The platform is suitable for NCE, life cycle management, reformulations, and repositioning; it can be used for a range of compounds; can generate stable formulations; and can be introduced into established manufacturing units.
The platform conforms to global monographs, is scalable from grams to tons quantities under excipient GMP manufacture; and is listed on the FDA inactive ingredient database, Grace reports.
Grace is exhibiting at CPhI Worldwide 2015, stand 7A24, Oct. 13–15, in Madrid, Spain.
Source: Grace